A Phase I/II Open-Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors

YUXIANG MA,† WENFENG FANG,† YANG ZHANG, YUNPENG YANG, SHAO DONG HONG, YUANYUAN ZHAO, AMOL TENDOLKAR, LU CHEN, DONG XU, JENNIFER SHENG, HONG YUN ZHAO, LI ZHANG

Departments of Clinical Research and Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, People’s Republic of China; Clinical Pharmacology and Pharmacometrics and Global Biometric Sciences, Bristol-Myers Squibb, Lawrenceville, New Jersey, USA; Global Clinical Research, Bristol-Myers Squibb, Shanghai, People’s Republic of China

†Contributed equally.

TRIAL INFORMATION

- ClinicalTrials.gov Identifier: NCT02593786
- Sponsor: Bristol-Myers Squibb Pharmaceuticals Ltd.
- Principal Investigator: Li Zhang
- IRB Approved: Yes

LESSONS LEARNED

- Nivolumab treatment at doses of 3 mg/kg once every 2 weeks (Q2W), 240 mg Q2W, and 360 mg once every 3 weeks was well tolerated in the Chinese population, with no new safety signals identified.
- Comparison of intensive pharmacokinetic profiles of nivolumab at 3 mg/kg Q2W in Chinese versus global populations revealed no ethnic differences of nivolumab treatment.
- Nivolumab shows promising preliminary antitumor activity in nasopharyngeal carcinoma.

ABSTRACT

Background. This phase I/II study investigated the safety and pharmacokinetics (PK) of nivolumab (anti-programmed cell death-1 monoclonal antibody) in Chinese patients with nasopharyngeal carcinoma (NPC) and other solid tumors.

Methods. A dose evaluation phase (3 mg/kg once every 2 weeks [Q2W]) was followed by a cohort expansion phase (3 mg/kg Q2W or flat doses of 240 mg Q2W or 360 mg once every 3 weeks).

Results. In the dose evaluation phase, 8/8 patients completed one cycle with no dose-limiting toxicities. At data cutoff, 46/51 patients were evaluable for safety (all cohorts). Treatment-related adverse events (TRAEs) occurred in 35 (76%) patients and were primarily grade 1–2; one patient (3 mg/kg Q2W) discontinued because of study drug toxicity. Intensive PK profiles at 3 mg/kg, 240 mg, and 360 mg were well characterized at single and multiple doses of nivolumab. An objective response was determined in six (6/46) patients, four (4/32) of whom had NPC tumors.

Conclusion. Nivolumab monotherapy at 3 mg/kg and flat doses of 240 mg and 360 mg were well tolerated in this Chinese patient population, with PK profiles at 3 mg/kg being similar to those of global patients. Preliminary efficacy results showed promising antitumor activity of nivolumab in advanced NPC.

The Oncologist 2019;24:891–e431

DISCUSSION

Nivolumab is a human monoclonal antibody that targets the programmed cell death-1 receptor. Nivolumab has been approved for the treatment of various types of cancer in >60 countries, and numerous clinical trials are ongoing. Although...
the overall efficacy, safety, and PK of nivolumab have been extensively studied, these data were established in predominantly Caucasian populations. The safety and intensive PK of nivolumab flat-dose regimens (240 mg Q2W or 360 mg once every 3 weeks) have not been assessed in Chinese patients.

This single-center, open-label, phase I/II study assessed the safety and tolerability of nivolumab in Chinese adult patients with previously treated, advanced or recurrent NPC or other solid tumors. Secondary objectives were PK, immunogenicity, and preliminary antitumor activity.

There were no new safety signals for nivolumab in Chinese patients, and safety profiles were consistent with prior clinical studies (Table 1). Of 46 evaluable patients, 35 experienced TRAEs; there were no grade 4–5 TRAEs, and only two were grade 3 (asthenia, 3 mg/kg cohort; hypochloremia, 240 mg cohort). Two serious TRAEs occurred, a grade 4 hyponatremia (3 mg/kg cohort) and an indeterminate grade pancreatitis and cerebellar hemorrhage (3 mg/kg cohort) that led to discontinuation.

Intensive PK profiles were characterized after first nivolumab dose and at steady state in all cohorts; PK data were compared with results from global patients and revealed no ethnic sensitivity at 3 mg/kg Q2W (Table 2). At data cutoff, antidrug antibodies were detected in 1 of 41 patients tested (3 mg/kg cohort).

Among the 32 patients (70%) with NPC, the objective response rate was 13% (95% confidence interval [CI]: 4–29) and the disease control rate was 66% (95% CI: 47–81). The median follow-up duration was 7.5 months (range: 0.8–24.7 months), and median progression-free survival was 3.5 months (95% CI: 1.8–5.5).

In this pretreated group of patients with predominantly NPC, our study showed that the safety, tolerability, and PK (3 mg/kg) of nivolumab are similar in Chinese and global populations. Furthermore, promising antitumor activity of nivolumab in NPC suggests that further studies are warranted.

Table 1. Summary of treatment-related adverse events and serious adverse events

| Adverse event | Chinese patients | Global patients | NPC (n = 32) |
|--------------|-----------------|----------------|-------------|
| Nivolumab 3 mg/kg (n = 15) | Nivolumab 240 mg (n = 20) | Nivolumab 360 mg (n = 11) | All patients (n = 46) |
| **Any grade** | **Grade 3–4** | **Grade 5** | **Any grade** | **Grade 3–4** | **Grade 5** | **Any grade** | **Grade 3–4** | **Grade 5** |
| Total TRAEs, n (%) | 12 (80) | 1 (7) | 0 | 14 (70) | 1 (5) | 0 | 9 (82) | 0 | 0 | 35 (76) | 2 (4) | 0 | 22 (69) | 1 (3) | 0 |
| TRAEs leading to discontinuation, n (%) | 1 (7) | 0 | 0 | 0 | 0 | 0 | 1 (2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

| TRAEs occurring in ≥10%, n (%) | | | |
| Hypothyroidism | 2 (13) | 5 (25) | 6 (55) | 13 (28) | 11 (34) |
| Rash | 2 (13) | 2 (10) | 4 (36) | 11 (24) | 8 (25) |
| Malaise | 2 (13) | 5 (25) | 7 (15) | 5 (11) | 4 (13) |
| Fatigue | 3 (20) | 2 (10) | 5 (11) | 5 (11) | 5 (11) |
| Decreased appetite | 2 (13) | 2 (10) | 2 (18) | 2 (18) | 2 (18) |
| Increased alanine aminotransferase | 2 (13) | 2 (10) | 2 (10) | 2 (10) | 2 (10) |
| Pyrexia | 2 (13) | 2 (10) | 2 (18) | 2 (18) | 2 (18) |
| Chest discomfort | 2 (13) | 2 (10) | 2 (18) | 2 (18) | 2 (18) |
| Diarrhea | 2 (13) | 2 (10) | 2 (18) | 2 (18) | 2 (18) |
| Nausea | 2 (13) | 2 (10) | 2 (18) | 2 (18) | 2 (18) |
| Dizziness | 2 (13) | 2 (10) | 2 (18) | 2 (18) | 2 (18) |
| Total treatment-related SAEs, n (%) | 1 (7) | 0 | 1 (5) | 1 (5) | 0 | 0 | 0 | 0 | 0 | 2 (4) | 1 (2) | 0 | 1 (3) | 1 (3) | 0 |

Table 2. Summary of pharmacokinetic parameters of nivolumab treatment (3 mg/kg, once every 2 weeks) in Chinese and global patient populations

| PK parameter | Chinese patients | Global patients | NPC (n = 32) |
|--------------|-----------------|----------------|-------------|
| Cmax, μg/mL | 57 (18) | 132 (17) | 61 (26) | 132 (20) |
| Tmax, hours | 4.0 (2.0–4.0) | 8.0 (4.0–16.0) | 2.1 (0.8–8.0) | 4.0 (1.0–8.0) |
| AUCtau, hours × μg/mL | 8,732 (24) | 30,824 (21) | 8,786 (23) | 30,640 (18) |
| 1/2/effective, hours | 366 (24) | — | 661 (202) | — |

Data for the global patient population are from the phase I CA209003 study [1].

© AlphaMed Press 2019
**TRIAL INFORMATION**

| Disease                  | Advanced cancer/solid tumor only |
|--------------------------|----------------------------------|
| Stage of Disease/Treatment | Metastatic/advanced              |
| Prior Therapy            | ≥1 prior regimen                 |
| Type of Study - 1        | Phase I/II                       |
| Type of Study - 2        | Dose evaluation and cohort expansion |
| Primary Endpoint         | Safety and tolerability          |
| Secondary Endpoint       | Pharmacokinetics                 |
| Secondary Endpoint       | Immunogenicity                    |
| Secondary Endpoint       | Efficacy                         |

**Additional Details of Endpoints or Study Design**
Dose evaluation and cohort expansion phases: Based on global clinical experience, a nivolumab dose of 3 mg/kg was selected for the initial 8-week dose evaluation phase. The study proceeded to the cohort expansion phase following the absence of dose-limiting toxicities in any of the treated patients. In the cohort expansion phase, three patient cohorts received differing nivolumab regimens (3 mg/kg, 240 mg, and 360 mg) until disease progression or unacceptable toxicity, for a maximum of 2 years. At the time of data analysis, a fourth expansion cohort (480 mg flat dose, once every 4 weeks [Q4W]) was active and not yet recruiting.

**Investigator’s Analysis**
Drug tolerable, efficacy undetermined

**DRUG INFORMATION**

**Drug 1**

| Generic/Working Name | Nivolumab |
|----------------------|-----------|
| Trade Name           | Opdivo    |
| Company Name         | Bristol-Myers Squibb Pharmaceuticals Ltd. |
| Drug Type            | Antibody  |
| Drug Class           | Immune therapy |
| Dose                 | 3 mg/kg, 240 mg, 360 mg |
| Route                | IV        |

**Schedule of Administration**
Dose evaluation phase: 3 mg/kg Q2W for 8 weeks. Cohort expansion phase: 3 mg/kg Q2W; or 240 mg flat dosing Q2W; 360 mg flat dosing once every 3 weeks (Q3W); 480 mg flat dosing Q4W. Note: At the time of data analysis, a fourth expansion cohort (480 mg flat dose Q4W) was active and not yet recruiting. The treatment cycles for the dose evaluation phase and 3 mg/kg Q2W and 240 mg Q2W dose expansion cohorts were 8 weeks’ duration (four doses per cycle), whereas the treatment cycles for the 360 mg Q3W cohort were 3 weeks’ duration (one dose per cycle).

**DOSE ESCALATION TABLE**

| Dose level       | Dose of drug: nivolumab               | Number enrolled | Number evaluable for toxicity |
|------------------|---------------------------------------|-----------------|-------------------------------|
| Cohort expansion | 3 mg/kg Q2W for 8-week cycle          | 15              | 15                            |
| Cohort expansion | 240 mg flat dose Q3W                   | 20              | 20                            |
| Cohort expansion | 360 mg flat dose Q3W                   | 11              | 11                            |

Abbreviations: Q2W, once every 2 weeks; Q3W, once every 3 weeks.

**DOSE INFORMATION: EVALUABLE SAFETY AND PK POPULATION**

|                      | Nivolumab 3 mg/kg, Q2W | Nivolumab 240 mg, Q2W | Nivolumab 360 mg, Q3W |
|----------------------|------------------------|-----------------------|-----------------------|
| n                    | 15                     | 20                    | 11                    |
| Number of doses      | 6 (1–51)               | 8 (1–48)              | 8 (1–15)              |
| Duration of therapy, weeks | 11.7 (2.0–105.1)   | 16.6 (2.0–98.7)       | 24.1 (3.0–48.9)       |
| Cumulative dose per subject | 18.2 (3.0–152.3) mg/kg| 1,920.0 (240.0–11,520.0) mg| 2,880.0 (360.0–5,076.0) mg|

Data are median (range).
### Patient Characteristics

|                          |       |
|--------------------------|-------|
| Number of Patients, Male | 31    |
| Number of Patients, Female | 15    |
| Stage                    | Advanced or recurrent |
| Age                      | Median (range): 48 (27–72) |
| Number of Prior Systemic Therapies | Median (range): 3 (1 to ≥4) |
| Performance Status: ECOG | 0 — 17, 1 — 29 |

Other

- Race: Asian 100%
- Complete baseline demographic and disease characteristics are presented in Table 3.

Cancer Types or Histologic Subtypes

- Hepatocellular carcinoma, 2
- Lung, non-small cell, 11
- Nasopharyngeal carcinoma, 32
- Not reported, 1

### Primary Assessment Method

| Title | New assessment |
|-------|----------------|
| Title | Total patient population |
| Number of Patients Screened | 51 |
| Number of Patients Enrolled | 51 |
| Number of Patients Evaluable for Toxicity | 46 |
| Number of Patients Evaluated for Efficacy | 46 |
| Evaluation Method | RECIST 1.1 |
| Response Assessment CR | *n* = 0 (0%) |
| Response Assessment PR | *n* = 6 (13%) |
| Response Assessment SD | *n* = 20 (43%) |
| Response Assessment PD | *n* = 18 (39%) |
| Response Assessment OTHER | *n* = 2 (4%) |

Outcome Notes

Regarding “Response Assessment OTHER,” responses could not be determined for these patients.

### Adverse Events

#### All-cause adverse events

| All phases, all cycles         | 1 | 2 | 3 | 4 | 5 | Total |
|-------------------------------|---|---|---|---|---|-------|
| Nivolumab 3 mg/kg (*n* = 15)  |   |   |   |   |   |       |
| Chest pain                    | 13%| 7%| 0%| 0%| 0%| 20%   |
| Fatigue                       | 20%| 0%| 0%| 0%| 0%| 20%   |
| Malaise                       | 13%| 7%| 0%| 0%| 0%| 20%   |
| Rash                          | 27%| 7%| 0%| 0%| 0%| 33%   |
| Decreased appetite            | 33%| 0%| 0%| 0%| 0%| 33%   |
| Hypoalbuminemia               | 7% | 7%| 0%| 0%| 0%| 13%   |
| Vomiting                      | 27%| 0%| 0%| 0%| 0%| 27%   |
| Diarrhea                      | 20%| 0%| 0%| 0%| 0%| 20%   |
| Abdominal discomfort          | 13%| 0%| 0%| 0%| 0%| 13%   |
| Constipation                  | 13%| 0%| 0%| 0%| 0%| 13%   |
| Nausea                        | 13%| 0%| 0%| 0%| 0%| 13%   |
| Dyspnea                       | 7% | 13%| 0%| 0%| 0%| 20%   |

© AlphaMed Press 2019
| Condition                                      | Nivolumab 240 mg (n = 20) | Nivolumab 360 mg (n = 11) |
|-----------------------------------------------|---------------------------|---------------------------|
| Dizziness                                     | 27% 0% 0% 0% 0% 27%       | 27% 0% 0% 0% 0% 27%       |
| Headache                                      | 20% 0% 0% 0% 0% 20%       | 27% 0% 0% 0% 0% 27%       |
| Increased alanine aminotransferase            | 20% 0% 0% 0% 0% 20%       | 20% 0% 0% 0% 0% 20%       |
| Decreased weight                              | 13% 7% 0% 0% 0% 13%       | 10% 0% 0% 0% 0% 10%       |
| Phlebitis                                     | 20% 0% 0% 0% 0% 20%       | 15% 0% 0% 0% 0% 15%       |
| Hypertension                                  | 0% 13% 0% 0% 0% 13%       | 10% 0% 0% 0% 0% 10%       |
| Malignant neoplasm progression                | 0% 0% 0% 0% 0% 20%       | 0% 0% 0% 0% 0% 20%       |
| Cancer pain                                   | 0% 13% 0% 0% 0% 13%       | 0% 13% 0% 0% 0% 13%       |
| Anemia                                        | 7% 7% 7% 0% 0% 13%       | 7% 7% 7% 0% 0% 13%       |
| Hypothyroidism                                | 0% 13% 0% 0% 0% 13%       | 0% 13% 0% 0% 0% 13%       |
| Musculoskeletal chest pain                    | 13% 0% 0% 0% 0% 13%       | 13% 0% 0% 0% 0% 13%       |
| Insomnia                                      | 20% 0% 0% 0% 0% 20%       | 20% 0% 0% 0% 0% 20%       |
| Malaise                                       | 30% 0% 0% 0% 0% 30%       | 30% 0% 0% 0% 0% 30%       |
| Pyrexia                                       | 10% 5% 5% 0% 0% 20%       | 10% 5% 5% 0% 0% 20%       |
| Fatigue                                       | 15% 0% 0% 0% 0% 15%       | 15% 0% 0% 0% 0% 15%       |
| Chills                                        | 10% 0% 0% 0% 0% 10%       | 10% 0% 0% 0% 0% 10%       |
| Pain                                          | 10% 0% 0% 0% 0% 10%       | 10% 0% 0% 0% 0% 10%       |
| Diarrhea                                      | 10% 5% 0% 0% 0% 15%       | 10% 5% 0% 0% 0% 15%       |
| Constipation                                  | 10% 0% 0% 0% 0% 10%       | 10% 0% 0% 0% 0% 10%       |
| Nausea                                        | 10% 0% 0% 0% 0% 10%       | 10% 0% 0% 0% 0% 10%       |
| Upper respiratory tract infection             | 20% 10% 0% 0% 0% 30%       | 20% 10% 0% 0% 0% 30%       |
| Pneumonia                                     | 0% 15% 5% 0% 0% 20%       | 0% 15% 5% 0% 0% 20%       |
| Increased alanine aminotransferase            | 20% 0% 0% 0% 0% 30%       | 20% 0% 0% 0% 0% 30%       |
| Increased aspartate aminotransferase          | 15% 5% 10% 0% 0% 30%       | 15% 5% 10% 0% 0% 30%       |
| Increased blood bilirubin                     | 0% 5% 10% 0% 0% 15%       | 0% 5% 10% 0% 0% 15%       |
| Decreased blood albumin                       | 10% 0% 0% 0% 0% 10%       | 10% 0% 0% 0% 0% 10%       |
| Increased C-reactive protein                  | 10% 0% 0% 0% 0% 10%       | 10% 0% 0% 0% 0% 10%       |
| Increased granulocyte count                   | 10% 0% 0% 0% 0% 10%       | 10% 0% 0% 0% 0% 10%       |
| Decreased hemoglobin                          | 10% 0% 0% 0% 0% 10%       | 10% 0% 0% 0% 0% 10%       |
| Anemia                                        | 0% 10% 10% 0% 0% 20%       | 0% 10% 10% 0% 0% 20%       |
| Leukocytosis                                  | 15% 0% 0% 0% 0% 15%       | 15% 0% 0% 0% 0% 15%       |
| Thrombocytosis                                | 10% 5% 0% 0% 0% 15%       | 10% 5% 0% 0% 0% 15%       |
| Dizziness                                     | 25% 0% 0% 0% 0% 25%       | 25% 0% 0% 0% 0% 25%       |
| Headache                                      | 10% 0% 0% 0% 0% 10%       | 10% 0% 0% 0% 0% 10%       |
| Hypothyroidism                                | 15% 15% 0% 0% 0% 30%       | 15% 15% 0% 0% 0% 30%       |
| Hyperthyroidism                               | 5% 5% 0% 0% 0% 10%       | 5% 5% 0% 0% 0% 10%       |
| Hyponatremia                                  | 0% 0% 20% 5% 0% 25%       | 0% 0% 20% 5% 0% 25%       |
| Hypochloremia                                 | 10% 0% 5% 0% 0% 15%       | 10% 0% 5% 0% 0% 15%       |
| Decreased appetite                            | 5% 5% 0% 0% 0% 10%       | 5% 5% 0% 0% 0% 10%       |
| Hypoaalbuminemia                              | 0% 10% 0% 0% 0% 10%       | 0% 10% 0% 0% 0% 10%       |
| Neck pain                                     | 10% 0% 0% 0% 0% 10%       | 10% 0% 0% 0% 0% 10%       |
| Malignant neoplasm progression                | 0% 0% 0% 0% 0% 20%       | 0% 0% 0% 0% 0% 20%       |
| Proteinuria                                   | 25% 0% 0% 0% 0% 25%       | 25% 0% 0% 0% 0% 25%       |
| Cough                                         | 10% 0% 0% 0% 0% 10%       | 10% 0% 0% 0% 0% 10%       |
| Rash                                          | 10% 5% 0% 0% 0% 15%       | 10% 5% 0% 0% 0% 15%       |
| Insomnia                                      | 10% 0% 0% 0% 0% 10%       | 10% 0% 0% 0% 0% 10%       |

Nivolumab 360 mg (n = 11)

| Condition                  | 27% 0% 0% 0% 0% 27%       |
|----------------------------|---------------------------|
| Constipation               | 27% 0% 0% 0% 0% 27%       |
| Vomiting                   | 27% 0% 0% 0% 0% 27%       |
| Hypothyroidism             | 46% 9% 0% 0% 0% 55%       |
Data represent percentage of all-cause adverse events occurring in ≥10% across any grade up to September 25, 2018 (database lock date for analysis of clinical data). Adverse events were graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.

### Serious Adverse Events

| All-cause serious adverse events | Grade | Attribution |
|---------------------------------|-------|-------------|
|                                 | 3     | 4           | 5           | Unknown     |                               |
| Nivolumab 3 mg/kg (n = 15)      |       |             |             |             |                               |
| Malignant neoplasm progression  | 0%    | 0%          | 20%         | 0%          | Unrelated                 |
| Brain edema                     | 7%    | 0%          | 0%          | 0%          | Unrelated                 |
| Cerebellar hemorrhage           | 0%    | 0%          | 0%          | 7%          | Treatment-related<sup>a</sup>|
| Pericardial effusion            | 7%    | 0%          | 0%          | 0%          | Unrelated                 |
| Pancreatitis                    | 0%    | 0%          | 0%          | 7%          | Treatment-related<sup>a</sup>|
| Septic shock                    | 0%    | 0%          | 7%          | 0%          | Unrelated                 |
| Respiratory failure             | 0%    | 7%          | 0%          | 0%          | Unrelated                 |
| Nivolumab 240 mg (n = 20)       |       |             |             |             |                               |
| Malignant neoplasm progression  | 0%    | 0%          | 20%         | 0%          | Unrelated                 |
| Lung infection                  | 5%    | 0%          | 0%          | 0%          | Unrelated                 |
| Pneumonia                       | 5%    | 0%          | 0%          | 0%          | Unrelated                 |
| Hypothalamo-pituitary disorder  | 5%    | 0%          | 0%          | 0%          | Unrelated                 |
| Dysphagia                       | 5%    | 0%          | 0%          | 0%          | Unrelated                 |
| Cholestatic Jaundice            | 5%    | 0%          | 0%          | 0%          | Unrelated                 |
| Hyponatremia                    | 0%    | 5%          | 0%          | 0%          | Treatment-related         |
| Asphyxia                        | 0%    | 0%          | 5%          | 0%          | Unrelated                 |
| Nivolumab 360 mg (n = 12)       |       |             |             |             |                               |
| Appendicitis                    | 9%    | 0%          | 0%          | 0%          | Unrelated                 |
| Muscular weakness               | 9%    | 0%          | 0%          | 0%          | Unrelated                 |

<sup>a</sup>Treatment-related pancreatitis and cerebellar hemorrhage in one patient led to discontinuation of study treatment.
Nivolumab is a human monoclonal antibody that targets the programmed death receptor-1 (PD-1) and has been approved for the treatment of various types of cancer in ≥60 countries [2]. Early-stage clinical trials of anti-PD-1 therapies have shown promising activity in recurrent or metastatic nasopharyngeal carcinoma (NPC), a common cancer in southeast Asia and North Africa [3, 4], with objective response rates (ORRs) of 21%–34% [5–7].

The overall efficacy, safety, and pharmacokinetics (PK) of nivolumab are based on clinical data from approximately 17,600 global (predominantly Caucasian) patients [8–15]. The safety of nivolumab 3 mg/kg administered once every 2 weeks (Q2W) has been assessed in Chinese patients in the CheckMate 078 study (NCT2613507), leading to its approval for the treatment of non-small cell lung cancer in China [16]; nivolumab 240 mg Q2W is approved in the U.S. [2] and Japan [17].

This study therefore aimed to assess the safety, tolerability, and PK of nivolumab in Chinese patients with previously treated, advanced or recurrent NPC or other solid tumors. Importantly, this is the first study to assess the safety and intensive PK of 240 mg and 360 mg flat-dose regimens in Chinese patients.

This was an open-label, single-center, phase I/II study (CheckMate 077; NCT02593786) of nivolumab monotherapy. The study comprised a dose evaluation phase (3 mg/kg Q2W, 60-minute intravenous [IV] infusion) and cohort expansion phase (3 mg/kg Q2W, flat dose 240 mg Q2W and 360 mg once every 3 weeks [Q3W]; 30-minute IV infusion) and consisted of a screening period (≥28 days), a treatment period (until disease progression or intolerable toxicities), and a follow-up period (≤100 days).

Included patients were Chinese adults (aged ≥18 years), Eastern Cooperative Oncology Group Performance Status 0 or 1, with histologically or cytologically confirmed solid tumors that were clinically advanced or recurrent, who had progressed after ≥1 prior line of systemic therapy. Exclusion criteria included central nervous system metastases, prior malignancy (except for nonmelanoma or certain in situ cancers, or complete remission ≥2 years), autoimmune disease, prior immunotherapy, active tuberculosis infection, pregnancy, or immunosuppressive agent treatment.

At data cutoff, 51 patients were enrolled, of whom 46 (90%) received ≥1 dose of study treatment and were evaluable for safety (Fig. 1). Baseline patient characteristics are presented in Table 3; the median patient age was 48 years (range: 27–72 years), 67% (31) were male, and 28 (61%) had received ≥2 prior lines of systemic anticancer therapy. Forty-three patients (93%) had discontinued during the treatment period, mostly because of disease progression (35 patients, 76%), and only 1 patient because of study drug toxicity. Three patients (7%) discontinued because of adverse events (AEs) unrelated to nivolumab.

At data cutoff, median (range) duration of treatment was 11.7 (2.0–105.1) weeks for the 3 mg/kg cohort, 16.6 (2.0–98.7) weeks for the 240 mg cohort, and 24.1 (3.0–48.9) weeks for the 360 mg cohort. The median (range) cumulative dose per subject was 1,920.0 (240.0–11,520.0) mg and 2,880.0 (360.0–5,076.0) mg for the 240 mg and 360 mg cohorts, respectively, and 18.2 (3.0–152.3) mg/kg in the 3 mg/kg cohort.

No dose-limiting toxicities were observed during the dose evaluation phase (n = 8) or dose expansion phase. Incidence of treatment-related adverse events (TRAEs) was similar across cohorts (Table 1). Overall, no new safety signals were identified, with safety profiles consistent with prior global studies and in line with a phase III study in Chinese patients (NCT02613507) [8–16, 18–20]. There were two grade ≥3 TRAEs: one grade 3 asthenia in the 3 mg/kg cohort and one grade 3 hypochloremia in the 240 mg cohort. Treatment-related serious adverse events were a grade 4 hyponatremia (240 mg cohort) and pancreatitis and cerebellar hemorrhage of indeterminate grade (one patient, 3 mg/kg cohort) that led to discontinuation of treatment. There were no incidences of death associated with nivolumab.

In terms of all-cause AEs, incidence of hypothyroidism was 30% in the 240 mg cohort (three patients each experienced a grade 1 or 2 event) and 55% in the 360 mg cohort (five patients with a grade 1 event and one patient with a grade 2 event) compared with no such reported events in the 3 mg/kg cohort. This most likely reflects the increased proportions of patients with NPC in the flat-dosing cohorts who had received prior radiotherapy.

Intensive PK profiles of nivolumab were characterized following a single dose (Cycle 1, Day 1) and multiple doses (3 mg/kg and 240 mg: Cycle 3, Day 1; 360 mg: Cycle 6, Day 1). Single-dose nivolumab resulted in rank-order differences in the mean serum concentration versus time profiles, with the highest mean concentrations observed for the 360 mg Q3W flat dose, followed by the 240 mg Q2W flat dose and the 3 mg/kg Q2W dose (Fig. 2A). PK parameters were assessed via noncompartmental analysis and showed similar rank-order relationships for the geometric mean area under the serum concentration-time curve for a dosing interval (AUCint), maximum serum concentration and concentration at the end of the dosing interval (Table 4).

Steady state was reached by approximately Cycle 3 (Week 17: 3 mg/kg and 240 mg flat dose) or Cycle 6 (Week 16: 360 mg flat dose; Fig. 2C). At steady state, the mean serum nivolumab concentration profiles over time were similar between the flat-dose cohorts and appeared lower for the 3 mg/kg cohort (Fig. 2B). The geometric mean AUCint for the 360 mg flat-dose cohort was approximately 41% and 72% higher than for the 240 mg flat-dose and 3 mg/kg cohorts, respectively. However, when normalized by dosing interval, the AUCint values were comparable, indicating that the different dosing regimens yielded comparable average concentrations at steady state. The mean effective half-life varied between cohorts (521–752 hours, or 21.7–31.3 days) but was within ±5 days of the mean elimination half-life of 25 days reported previously [2].

At 3 mg/kg, nivolumab exposure in Chinese patients was similar to that of patients in a global phase I study (NCT00730639), as demonstrated by a cross-study comparison (Table 2) [1]. These data are also in agreement with a recent phase I study of nivolumab in advanced solid tumors in Korean patients, in which PK data were shown to be comparable to U.S. and Japanese populations [21].

Immunogenicity was assessed via antidrug antibody (ADA) status (Table 5). Of 41 evaluable patients, only 1 patient (3 mg/kg cohort) was ADA positive after treatment. None of the patients were persistently ADA positive or neutralizing antibody positive.
Preliminary antitumor activity was assessed for patients with NPC tumors and for patients with all other solid tumors. Of 32 patients with NPC, 15 (47%) had a reduction in tumor burden from baseline following nivolumab treatment (Fig. 3). Four patients (13%) achieved a partial response (two patients each, 3 mg/kg and 240 mg cohorts), and 17 (53%) had stable disease. The ORR and disease control rate (DCR) in this patient group were 13% (95% confidence interval [CI]: 4–29) and 66% (95% CI: 47–81), respectively (Table 6; Fig. 4). Patients with other solid tumor types achieved an ORR of 14% and a DCR of 36%.

The median (range) follow-up duration for patients with NPC was 7.5 (0.8–24.7) months, with six patients (19%) having received nivolumab treatment for >1 year. Median progression-free survival (PFS) was 3.5 months (95% CI: 1.8–5.5 months), and median overall survival (OS) was not reached. The 3-month PFS and OS rates were 64.2% (95% CI: 44.7–78.4) and 87.5% (95% CI: 70.0–95.1), respectively.

This study confirms the safety profile of nivolumab at 3 mg/kg in Chinese patients and is the first to report tolerability at flat doses of 240 mg and 360 mg in this population. Additionally, these data indicate that the PK of nivolumab monotherapy are ethnically insensitive. In this population of pretreated patients with advanced or recurrent disease, preliminary antitumor responses in NPC are encouraging; confirmation is required in a larger patient population.

ACKNOWLEDGMENTS
The authors thank the patients and families that made this trial possible; the clinical study teams who participated in the trial; Bristol-Myers Squibb; ONO Pharmaceutical Company Ltd. (Osaka, Japan). BMS policy on data sharing may be found at https://www.bms.com/researchers-and-partners/independent-research/data-sharing-requestprocess.html. This study was funded by Bristol-Myers Squibb. Editorial assistance in manuscript preparation was provided by Susanah Thornhill and Tim Stentiford of MediTech Media, Asia Pacific, and funded by Bristol-Myers Squibb China.

DISCLOSURES
Amol Tendolkar: Bristol-Myers Squibb (E, OI); Lu Chen: Bristol-Myers Squibb (E); Dong Xu: Bristol-Myers Squibb (E); Jennifer Sheng: Bristol-Myers Squibb (E, OI); Li Zhang: Hengrui Medicine Co., Ltd., Eli Lilly, Novartis, Roche, Bristol-Myers Squibb (RF). The other authors indicated no financial relationships.

(C/A) Consulting/advisory relationship; (RF) Research funding; (E) Employment; (ET) Expert testimony; (H) Honoraria received; (O) Ownership interests; (IP) Intellectual property rights/inventor/patent holder; (SAB) Scientific advisory board

REFERENCES
1. Center for Drug Evaluation and Research. Clinical Pharmacology and Biopharmaceutics Reviews. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125554Orig1s000ClinPharmR.pdf. Accessed April 2019.
2. Opdivo. Prescribing Information. United States Food and Drug Administration. April 2018, 12 December 2018. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s058lbl.pdf. Accessed April 2019.
3. Carioli G, Negri E, Kawakita D et al. Global trends in nasopharyngeal cancer mortality since 1970 and predictions for 2020: Focus on low-risk areas. Int J Cancer 2017;140:2256–2264.
4. Wang Y, Shen C, Lu X et al. The incidence and prognosis of nasopharyngeal carcinoma patients with family history. Oncotarget 2017;8:97323–97330.
5. Hsu C, Lee SH, Ejadi S et al. Safety and antitumor activity of pembrolizumab in patients with programmed-death-ligand 1-positive nasopharyngeal carcinoma: Results of the KEYNOTE-028 study. J Clin Oncol 2017;35:4050–4056.
6. Fang W, Yang Y, Ma Y et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol 2018;19:1338–1350.
7. Ma BBY, Lim WT, Goh BC et al. Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: An international, multicenter study of the Mayo Clinic Phase 2 Consor- tium (NCI-9742). J Clin Oncol 2018;36:1412–1418.
8. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627–1639.
9. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123–135.
10. Motzer RJ, Escudier B, McDermott DF et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803–1813.
11. Younes A, Santoro A, Shipp M et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol 2016;17:1283–1294.
12. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 2015;372:311–319.
13. Ferris RL, Blumenschein G Jr, Fayette J et al. Nivolumab for recurrent squamous-cell carci- noma of the head and neck. N Engl J Med 2016;375:1856–1867.
14. Sharma P, Retz M, Sieffer-Radkte A et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multi- centre, single-arm, phase 2 trial. Lancet Oncol 2017;18:312–322.
15. Overman MJ, McDermott R, Leach JL et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol 2017;18:1182–1191.
16. Wu Y, Lu S, Cheng Y et al. Abstract CT114: Nivolumab versus docetaxel in a predominantly Chi- nese patient population with previously treated advanced non-small cell lung cancer (NSCLC): Results of the phase 3 CheckMate 078 study. Cancer Res 2018;78:CT114a.
17. Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb. Opdivo approved for supplemental applications for expanded indications of malignant pleural mesothelioma and adjuvant treatment of melanoma change in dosage and administration of single dosing regimen and expanded indication of renal cell carcinoma in Opdivo and Yervoy com- bination therapy. Available at https://www.ono. co.jp/en/news/pdf/sm_cn180821.pdf. Accessed December 22, 2018.
18. Robert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015;372:320–330.
19. Weber JS, D’ Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015;16:375–384.
20. Gettinger S, Horn L, Jackman D et al. Five- year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer: Results From the CA209-003 study. J Clin Oncol 2018;36:1675–1684.
21. Lee KW, Lee DH, Kang JH et al. Phase I phar- macokinetic study of nivolumab in Korean patients with advanced solid tumors. The Oncologist 2018;23:155–157.
51 patients enrolled

46 patients treated

Nivolumab 240mg
(n = 20)

Disease progression: 12 (80%)
Study drug toxicity: 1 (7%)
AE unrelated to nivolumab: 1 (7%)
Other*: 1 (7%)

Nivolumab 3mg/kg
(n = 15)

Disease progression: 15 (75%)
AE unrelated to nivolumab: 1 (7%)
Patient request: 2 (10%)
Not reported: 1 (5%)

Nivolumab 360mg
(n = 11)

Disease progression: 8 (73%)
AE unrelated to nivolumab: 1 (9%)
Screening failure: 4 (8%)
Other reason for discontinuation: 1 (2%)

0 patients continuing treatment period

1 (5%) patient continuing treatment period

2 (18%) patient continuing treatment period

Figure 1. Patient disposition flow chart. *Death due to septic shock considered unrelated to the study drug. †Treatment status unconfirmed at the time of database lock.

Abbreviation: AE, adverse event.

Figure 2. Pharmacokinetics of nivolumab. (A): Mean serum concentration-time profiles of nivolumab after single-dose administration. (B): Mean serum concentration-time profiles of nivolumab at steady state. (C): Geometric mean trough concentration profiles of nivolumab. For all figures: A, 3 mg/kg; B, 240 mg; C, 360 mg. Logarithmic scale. Bars indicate SD.
Figure 3. Waterfall plot of best reduction from baseline in target lesions for patients with nasopharyngeal carcinoma. Abbreviation: PR, partial response.

Figure 4. Tumor swimmer plot for the subpopulation of patients with nasopharyngeal carcinoma. Abbreviations: PR, partial response; SD, stable disease.
Table 3. Baseline patient characteristics and prior cancer therapy

| Characteristics, n (%)                     | Nivolumab 3 mg/kg (n = 15) | Nivolumab 240 mg (n = 20) | Nivolumab 360 mg (n = 11) | Total (n = 46) |
|-------------------------------------------|-----------------------------|---------------------------|---------------------------|-----------------|
| **Male**                                  | 11 (73)                    | 13 (65)                   | 7 (64)                    | 31 (67)         |
| **Age, median (range), years**            |                             |                           |                           |                 |
|                                           | 52 (27–59)                 | 45 (29–60)                | 53 (30–72)                | 48 (27–72)      |
| **ECOG status**                           |                             |                           |                           |                 |
| 0                                         | 8 (53)                     | 5 (25)                    | 4 (36)                    | 17 (37)         |
| 1                                         | 7 (47)                     | 15 (75)                   | 7 (64)                    | 29 (63)         |
| **Tumor type**                            |                             |                           |                           |                 |
| NSCLC                                     | 9 (60)                     | 1 (5)                     | 1 (9)                     | 11 (24)         |
| NPC                                       | 6 (40)                     | 17 (85)                   | 9 (82)                    | 32 (70)         |
| HCC                                       | 2 (10)                     |                           |                           | 2 (4)           |
| Not reported                              | 1 (9)                      |                           |                           | 1 (2)           |
| **Weight, median (range), kg**            | 57.5 (44.9–73.6)           | 62.3 (36.2–78.4)          | 59.0 (37.0–69.7)          | 59.7 (36.2–78.4) |
| **Prior surgery**                         |                             |                           |                           |                 |
| Yes                                       | 15 (100)                   | 20 (100)                  | 2 (18)                    | 37 (80)         |
| No                                        | 0                          | 0                         | 9 (82)                    | 9 (20)          |
| **Prior radiotherapy**                    |                             |                           |                           |                 |
| Yes                                       | 10 (67)                    | 17 (85)                   | 11 (100)                  | 38 (83)         |
| No                                        | 5 (33)                     | 3 (15)                    | 0                         | 8 (17)          |
| **Prior systemic therapy, number of regimens** |                 |                           |                           |                 |
| 1                                         | 0                          | 4 (20)                    | 0                         | 4 (9)           |
| 2                                         | 5 (33)                     | 3 (15)                    | 6 (55)                    | 14 (30)         |
| 3                                         | 1 (7)                      | 6 (30)                    | 2 (18)                    | 9 (20)          |
| ≥4                                        | 9 (60)                     | 7 (35)                    | 3 (27)                    | 19 (41)         |

Abbreviations: ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; NPC, nasopharyngeal carcinoma; NSCLC, non-small cell lung cancer.

Table 4. Summary pharmacokinetic parameters of nivolumab

| PK parametera | Nivolumab 3 mg/kg | Nivolumab 240 mg | Nivolumab 360 mg |
|---------------|-------------------|------------------|------------------|
|               | Cycle 1, Day 1 (n = 15) | Cycle 3, Day 1 (n = 7) | Cycle 1, Day 1 (n = 20) | Cycle 3, Day 1 (n = 9) | Cycle 1, Day 1 (n = 11) | Cycle 6, Day 1 (n = 7) |
| Cmax, μg/mL   | 57 (18)            | 132 (17)         | 78 (18)          | 172 (14)         | 108 (21)            | 165 (24)            |
| Tmax, hours   | 4.0 (0.5–4.0)      | 8.0 (4.0–48.2)   | 4.0 (0.5–8.0)    | 8.0 (4.0–48.0)   | 4.0 (4.0–8.0)       | 8.0 (0.5–24.1)     |
| AUCtau, hours × μg/mL | 8,732 (24)          | 30,824 (21)      | 12,112 (24)      | 37,794 (22)      | 23,567 (17), n = 10 | 53,162 (40)        |
| Css-avg, μg/mL | 92.7 (20)          | 62 (24)          | 98.6 (28)        | 98.6 (28)        | 98.6 (28)           | 98.6 (28)           |
| Ct, μg/mL     | 16 (26), n = 13    | 65 (27), n = 6   | 20 (30), n = 18  | 78 (31), n = 8   | 26 (17), n = 10    | 66 (35), n = 6     |
| t1/2-effective, hours | 566 (24)          | 521 (22)         | 752 (56)         | 752 (56)         | 752 (56)            | 752 (56)            |

**Geometric mean (% coefficient of variation [CV]) for all parameters except for Tmax (median [range]) and t1/2-effective (mean [% CV]). Abbreviations: AUCtau, area under the serum concentration-time curve in one dosing interval; Cmax, maximum serum concentration; Css-avg, average concentration over a dosing interval, calculated at steady state; Ct, observed trough concentration; Ct, concentration at the end of the dosing interval; PK, pharmacokinetic; t1/2-effective, effective half-life calculated using the formula \( r \ln(2) / \ln(AI) \), where t is the dosing interval and AI is the ratio of AUCtau at steady state to that at single dose; Tmax, time taken to reach maximum concentration.**
### Table 5. Nivolumab treatment immunogenicity

| ADA status, n (%) | Nivolumab 3 mg/kg (n = 13) | Nivolumab 240 mg (n = 18) | Nivolumab 360 mg (n = 10) | Total (n = 41) |
|------------------|---------------------------|---------------------------|---------------------------|---------------|
| ADA positive<sup>a</sup> | 1 (8) | 0 | 0 | 1 (2) |
| pp<sup>b</sup> | 0 | 0 | 0 | 0 |
| Not PP–last sample positive<sup>c</sup> | 1 (8) | 0 | 0 | 1 (2) |
| Other positive<sup>d</sup> | 0 | 0 | 0 | 0 |
| Neutralizing positive<sup>e</sup> | 0 | 0 | 0 | 0 |
| ADA negative | 12 (92) | 18 (100) | 10 (100) | 40 (98) |

<sup>a</sup>At least one ADA-positive (ADA+) sample relative to baseline after treatment initiation.

<sup>b</sup>ADA+ samples at ≥2 consecutive timepoints.

<sup>c</sup>Not PP, but ADA+ during the last sampling.

<sup>d</sup>Not PP, some ADA+, with the last sampling being negative.

<sup>e</sup>At least one ADA+ sample with neutralizing antibodies detected after baseline. Data shown are for patients with baseline ADA data and at least one post-baseline ADA assessment.

Abbreviations: ADA, antidrug antibody; PP, persistent positive.

### Table 6. Antitumor responses

| Antitumor response | Nivolumab 3 mg/kg | Nivolumab 240 mg | Nivolumab 360 mg | Total |
|--------------------|-------------------|------------------|------------------|-------|
|                    | NPC (n = 6)       | Other (n = 9)    | NPC (n = 17)     | Other (n = 2) |
| Best overall response, n (%) |                    |                  |                  |       |
| Complete response | 0                  | 0                | 0                | 0     |
| Partial response  | 2 (33)             | 1 (11)           | 2 (12)           | 0     |
| Stable disease    | 1 (17)             | 1 (11)           | 10 (59)          | 2 (67) |
| Progressive disease | 2 (33)             | 7 (78)           | 4 (24)           | 1 (33) |
| Undetermined      | 1 (17)             | 0                | 1 (6)            | 0     |
| Objective response rate<sup>a</sup>, n (%) [95% CI]<sup>b</sup> | 2 (33) | 1 (11) | 2 (12 [2–36]) | 0 | 0 | 1 (50) | 4 (13 [4–29]) | 2 (14) |
| Disease control rate<sup>c</sup>, n (%) [95% CI]<sup>b</sup> | 3 (50) | 2 (22) | 12 (71 [44–90]) | 2 (67) | 6 (67) | 1 (50) | 21 (66 [47–81]) | 5 (36) |

<sup>a</sup>The proportion of patients whose best overall response is either a complete response or a partial response.

<sup>b</sup>Confidence intervals were computed for cohorts of 10 patients or more only.

<sup>c</sup>The proportion of patients with a complete response, with a partial response, or who achieved stable disease.

Abbreviations: CI, confidence interval; NPC, nasopharyngeal carcinoma.